×

Tag: Cyclarity

Matthew O'Connor Interview
Cyclarity Therapeutics is developing an affordable, plaque-busting small molecule that may be the cure for the world's number one killer: cardiovascular disease. With human trials planned for this year, we decided that it was time to catch up with Cyclarity and its CEO of Scientific Affairs, Dr. Matthew O’Connor, to see how things were going....
Matthew O'Connor Interview
Cyclarity Therapeutics is striving to make powerful treatments for cardiovascular disease and, most importantly, make them accessible and affordable. Their cutting-edge cyclodextrin technology targets atherosclerosis, aiming to eliminate the buildup of non-degradable oxidized cholesterol that gets stuck inside cells in the arterial walls. The company has made great progress towards launching its cyclodextrin drug for...